cases of locally advanced non small cell lung cancer (diagnosed by PET/CT scan and histopathological confirmation) will be screened for sleep disorders by Epworth sleepiness scale then confirmed by full night polysomnographic study. Blood sample to detect some genetic determinants will be withdrawn
Study Type
OBSERVATIONAL
Enrollment
50
full night polysomnographic study and blood sample to detect some genetic issues
Ahmad Abbas
Zagazig, Asharqia, Egypt
assessment Response to treatment
CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)
Time frame: 6 weeks from ending therapy
confirmed Response to treatment
CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)
Time frame: 4 weeks from assessment response
Progression Free Survival
CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)
Time frame: 3 months from confirmed response to treatment
Progression Free Survival
CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)
Time frame: 6 months from confirmed response to treatment
Progression Free Survival
CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)
Time frame: 9 months from confirmed response to treatment
Progression Free Survival
CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)
Time frame: 12 months from confirmed response to treatment
Overall survival
regular patient follow up visit
Time frame: 3 months after enrollment
Overall survival
regular patient follow up visit
Time frame: 6 months after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Overall survival
regular patient follow up visit
Time frame: 9 months after enrollment
Overall survival
regular patient follow up visit
Time frame: 12 months after enrollment